Published in Br J Pharmacol on October 01, 1971
Effect of heparin administration on plasma binding of benzodiazepines. Br J Clin Pharmacol (1980) 0.91
Drug displacement from protein binding: source of the sulphadoxine liberated by phenylbutazone. Br J Pharmacol (1971) 0.81
The binding of antibiotics to serum proteins. Br J Pharmacol Chemother (1965) 5.04
The physiological disposition of phenylbutazone (butazolidin) in man and a method for its estimation in biological material. J Pharmacol Exp Ther (1953) 3.60
The determination of sulphanilamide and its derivatives. Biochem J (1941) 2.36
The binding of drugs by plasma proteins. J Pharm Sci (1968) 1.69
Displacement of one drug by another from carrier or receptor sites. Proc R Soc Med (1965) 1.68
Enzyme stimulation and inhibition in the metabolism of drugs. Proc R Soc Med (1965) 1.34
A drug-induced change in the distribution and renal excretion of sulfonamides. J Pharmacol Exp Ther (1961) 1.31
Progress in sulfonamide research. Prog Drug Res (1968) 1.04
[Physicochemical and biological studies on sulfonamides. 1. Pharmacologically interesting physicochemical characteristics of 21 sulfonamides and 6 sulfonamide metabolites]. Arzneimittelforschung (1963) 1.02
The binding of three penicillins in the plasma of several mammalian species as studied by ultrafiltration at body temperature. Br J Pharmacol Chemother (1965) 0.94
Displacement from protein binding of sulphormethoxine by phenylbutazone using in vivo dialysis in rats. Br J Pharmacol (1969) 0.82
Drug displacement from protein binding: source of the sulphadoxine liberated by phenylbutazone. Br J Pharmacol (1971) 0.81
The drug lag revisited: comparison by therapeutic area of patterns of drugs marketed in the United States and Great Britain from 1972 through 1976. Clin Pharmacol Ther (1978) 2.02
Results of Hypotensive Therapy in Arterial Hypertension. Br Med J (1961) 1.84
Transport of gold in the body. Ann Rheum Dis (1969) 1.77
Introduction of new therapeutic drugs in the United States and Great Britain: an international comparison. Clin Pharmacol Ther (1973) 1.64
Therapeutic implications of the drug lag. Clin Pharmacol Ther (1974) 1.61
Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: issues of safety. Clin Pharmacol Ther (1984) 1.59
Subcutaneous fluid administration in elderly subjects: validation of an under-used technique. J Am Geriatr Soc (1991) 1.49
Immunofluorescent localization of Tamm-Horsfall mucoprotein in human kidney. J Clin Pathol (1969) 1.46
The rate of development of new drugs in the United States, 1963 through 1975. Clin Pharmacol Ther (1978) 1.41
The measurement of pharmaceutical innovation. J Clin Pharmacol (1980) 1.18
Plasma half-life of clofibric acid in renal failure. Br J Clin Pharmacol (1979) 1.14
Factors determining the aggregation of urinary mucoprotein. J Clin Pathol (1966) 1.13
Protein binding of indomethacin: binding of indomethacin to human plasma albumin and its displacement from binding by ibuprofen, phenylbutazone and salicylate, in vitro. Pharmacology (1974) 1.12
Clinical trials and tribulations. Arch Intern Med (1974) 1.11
The development of self-originated new drugs by Swiss pharmaceutical firms, 1960-1980. Regul Toxicol Pharmacol (1984) 1.10
Serum clofibrate concentrations in patients on continuous medication. Pharmacology (1974) 1.09
A close inspection of the "calm look". Rhetorical amblyopia and selective amnesia at the Food and Drug Administration. JAMA (1978) 1.08
Vascular reactivity in experimental hypertension. N Z Med J (1968) 1.07
Composition of urinary casts. Lancet (1966) 1.06
Parotid and whole saliva in the prediction of serum total and free phenytoin concentrations. Clin Pharmacol Ther (1978) 0.97
Patients' needs in drug development and regulation. Ann N Y Acad Sci (1981) 0.97
Postmarketing surveillance of new drugs: I. Review of objectives and methodology. J Clin Pharmacol (1979) 0.96
Drug development, regulation, and the practice of medicine. JAMA (1974) 0.95
Measurement of clofibric acid (CPIB) metabolites in plasma of patients on clofibrate therapy. Clin Exp Pharmacol Physiol (1979) 0.94
Residual effects of hypnotics: triazolam, flurazepam, and nitrazepam. Psychopharmacology (Berl) (1980) 0.88
Analgesic activity of oral naproxen in patients with postoperative pain. Scand J Rheumatol Suppl (1973) 0.88
The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. N Z Med J (1980) 0.87
Development of new drugs originated and acquired by United States-owned pharmaceutical firms, 1963-1976. Clin Pharmacol Ther (1980) 0.87
Anti-inflammatory drug mechanisms. Drugs (1973) 0.86
Methanol monitoring. Comparison of urinary methanol concentration with formic acid excretion rate as a measure of occupational exposure. Int Arch Occup Environ Health (1980) 0.85
Fluroxene and the penicillin lesson. Anesthesiology (1973) 0.84
Success rates in the United States drug development system. Clin Pharmacol Ther (1984) 0.84
Adverse reactions to drugs: a comprehensive hospital inpatient survey. N Z Med J (1972) 0.84
Sweating and peripheral blood flow in patients with phaeochromocytoma. Clin Sci (1969) 0.82
Displacement from protein binding of sulphormethoxine by phenylbutazone using in vivo dialysis in rats. Br J Pharmacol (1969) 0.82
Lack of correlation between strength of contractions and oxygen consumption of drug-treated, directly-stimulated rat diaphragm [proceedings]. Br J Pharmacol (1978) 0.81
Drug displacement from protein binding: source of the sulphadoxine liberated by phenylbutazone. Br J Pharmacol (1971) 0.81
Hormonal steroid contraceptives. 3. Adverse reactions. Drugs (1971) 0.81
Consultative services in clinical pharmacology. J Clin Pharmacol (1976) 0.81
Effect of naloxone on the analgesic activity of methadone in a 1:10 oral combination. Time and cost of flirting with the null hypothesis in tests of equivalence. Clin Pharmacol Ther (1974) 0.81
The measurement of therapeutic value. J Clin Pharmacol (1980) 0.81
Postmarketing surveillance of new drugs: II. Case studies. J Clin Pharmacol (1979) 0.81
The binding of gold to cytosolic proteins of the rat liver and kidney tissues: metallothioneins. Biochem Pharmacol (1980) 0.80
The US Drug Efficacy Study and its implication (DESI). Agents Actions (1978) 0.80
Coupling resistance of double barrelled microelectrodes. Nature (1967) 0.80
Control of drug utilization in the context of a national health service: the New Zealand system. Clin Pharmacol Ther (1974) 0.80
Comparison of tissue fluid and plasma concentrations of a protein-bound drug sulphormethoxine by in vivo dialysis in rats. Br J Pharmacol Chemother (1968) 0.80
The subcellular distribution of gold in monkey liver, kidney and spleen, in vivo. Clin Exp Pharmacol Physiol (1980) 0.79
Electrical and pharmacological properties of mammalian neuroglial cells in tissue-culture. Proc R Soc Lond B Biol Sci (1966) 0.79
Blood levels of hexachlorophene in neonates. Aust Paediatr J (1972) 0.79
Separation of two conjugates of clofibric acid (CPIB) found in the urine of subjects taking clofibrate. Clin Exp Pharmacol Physiol (1978) 0.79
Modification of the pH method to enable rapid microbiological assay of a wide range of antibiotics. Med J Aust (1971) 0.79
Adverse drug reactions in a general hospital. N Z Med J (1973) 0.79
Serial hexachlorophene blood levels in the premature infant. N Z Med J (1975) 0.78
Methodology for demonstrating sustained efficacy of hypnotics: a comparative study of triazolam and flurazepam. Clin Pharmacol Ther (1979) 0.77
Pharmacokinetics of lithium: elimination half-time, renal clearance and apparent volume of distribution in schizophrenia. Clin Pharmacokinet (1978) 0.77
Analgesic efficacy of an orally administered combination of pentazocine and aspirin. With observations on the use and statistical efficiency of GLOBAL subjective efficacy ratings. Clin Pharmacol Ther (1977) 0.76
Effects of gold sodium thiomalate on cytosolic copper and zinc in the rat kidney and liver tissues. Clin Exp Pharmacol Physiol (1982) 0.76
Noradrenaline release from slices of the thalamus of normal and morphine-dependent rats. Naunyn Schmiedebergs Arch Pharmacol (1980) 0.76
New drug development during and after a period of regulatory change: clinical research activity of major United States pharmaceutical firms, 1958 to 1979. Clin Pharmacol Ther (1983) 0.76
Effect of halofenate on the serum binding of phenytoin. Br J Clin Pharmacol (1977) 0.75
Lest we forget. Aust N Z J Med (1990) 0.75
Analgesic efficacy of parenteral metkephamid acetate in treatment of postoperative pain. Lancet (1982) 0.75
ASH. Selective acronym? N Z Med J (1992) 0.75
The patient with haematuria. N Z Med J (1993) 0.75
An unfortunate (start to a) leading article. N Z Med J (1989) 0.75
Modeling of subcutaneous absorption kinetics of infusion solutions in the elderly using technetium. J Pharmacokinet Biopharm (1997) 0.75
Model representation of salicylate pharmacokinetics using unbound plasma salicylate concentrations and metabolite urinary excretion rates following a single oral dose. J Pharmacokinet Biopharm (1991) 0.75
Dangers of barbiturates. Br Med J (1970) 0.75
Hormonal steroid contraceptives. IV. Adverse reactions and management of the patient. Drugs (1971) 0.75
Hormonal steroid contraceptives: a further review of adverse reactions. Drugs (1978) 0.75
New Zealand Committee on Adverse Drug Reactions. Tenth Annual Report 1975. N Z Dent J (1976) 0.75
New Zealand Committee on Adverse Drug Reactions: Eleventh Annual Report 1976. N Z Dent J (1977) 0.75
New Zealand Committee on Adverse Drug Reactions: Twelfth Annual Report 1977. N Z Med J (1977) 0.75
Management of drug poisoning. N Z Med J (1967) 0.75
Drug displacement from protein-binding and redistributional interactions. Prog Biochem Pharmacol (1974) 0.75
New Zealand committee on adverse drug reactions: Twelfth annual report 1977. N Z Dent J (1978) 0.75
Urinary excretion of rifampicin and its metabolites as an index of rifampicin blood levels. N Z Med J (1970) 0.75
Letter: ADR's. JAMA (1975) 0.75
Oestrogen content of oral contraceptives and thromboembolism. N Z Med J (1970) 0.75
Indomethacin estimation in plasma and serum by electron capture gas chromatography. J Chromatogr (1974) 0.75
Salicylate toxicology. Agents Actions Suppl (1977) 0.75
Blood level estimation in phenytoin treatment of epilepsy. N Z Med J (1975) 0.75
The prevalence of asthma. N Z Med J (1995) 0.75
Antibiotic allergy and acute renal failure. N Z Med J (1965) 0.75
Hexachlorophene analysis in blood by electron capture gas chromatography. J Chromatogr (1973) 0.75
Urinary mucoprotein and cast formation. N Z Med J (1968) 0.75
Effect of phenytoin and other drugs in reducing serum DDT levels. N Z Med J (1972) 0.75
Poisoning from a rose spray containing lindane and malathion. N Z Med J (1968) 0.75
New Zealand Committee on Adverse Drug Reactions: eleventh annual report 1976. N Z Med J (1976) 0.75
Acute glomerulitis in pregnancy. Aust N Z J Obstet Gynaecol (1966) 0.75
Dissolution rates of phenylbutazone. N Z Med J (1972) 0.75
Teratogenicity of drugs. N Z Vet J (1972) 0.75
Hexachlorophane. Drugs (1973) 0.75
Clinical pharmacology in New Zealand. Med J Aust (1971) 0.75
New Zealand Committee on Adverse Drug Reactions: Ninth Annual Report 1974. N Z Med J (1974) 0.75
Hereditary angioneurotic oedema. N Z Med J (1973) 0.75
Betamethasone in stroke. N Z Med J (1978) 0.75
Paraquat poisoning. N Z Med J (1976) 0.75
New Zealand Committee on Adverse Drug Reactions: Tenth Annual Report 1975. N Z Med J (1975) 0.75